# VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases

> **NCT05099094** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai BDgene Co., Ltd.** · enrollment: 3 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration
- Diabetic Macular Edema
- Retinal Vein Occlusion

## Interventions

- **GENETIC:** BD311

## Key facts

- **NCT ID:** NCT05099094
- **Lead sponsor:** Shanghai BDgene Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-25
- **Primary completion:** 2024-11-30
- **Final completion:** 2025-09
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2025-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05099094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05099094, "VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05099094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*